Who Generates Higher Gross Profit? Ascendis Pharma A/S or Jazz Pharmaceuticals plc

Jazz Pharmaceuticals' gross profit outshines Ascendis Pharma's by over 10x.

__timestamp	Ascendis Pharma A/S	Jazz Pharmaceuticals plc
Wednesday, January 1, 2014	13983000	1055457000
Thursday, January 1, 2015	8118000	1222277000
Friday, January 1, 2016	4606000	1382587000
Sunday, January 1, 2017	1530000	1508505000
Monday, January 1, 2018	10581000	1769378000
Tuesday, January 1, 2019	13375000	2033831000
Wednesday, January 1, 2020	6953000	2214650000
Friday, January 1, 2021	4255000	2653478000
Saturday, January 1, 2022	39037000	3118857000
Sunday, January 1, 2023	222323000	3398627000
Monday, January 1, 2024	319383000

In pursuit of knowledge

A Tale of Two Biopharma Giants: Ascendis Pharma A/S vs. Jazz Pharmaceuticals plc

In the competitive world of biopharmaceuticals, gross profit is a key indicator of a company's financial health and market prowess. Over the past decade, Jazz Pharmaceuticals plc has consistently outperformed Ascendis Pharma A/S in generating gross profit. From 2014 to 2023, Jazz Pharmaceuticals saw a staggering increase of over 220% in gross profit, peaking at approximately $3.4 billion in 2023. In contrast, Ascendis Pharma A/S, while showing growth, reached its highest gross profit of around $222 million in the same year.

This stark difference highlights Jazz Pharmaceuticals' dominant market position, with its gross profit consistently being over ten times that of Ascendis Pharma A/S. As the biopharma industry continues to evolve, these figures underscore the importance of strategic investments and market expansion in driving financial success.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025